Randomized trial · people
Pemvidutide: liver fat down 54.7% at 48 weeks in IMPACT MASH trial
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In people with MASH and stage F2 or F3 fibrosis, liver fat and non-invasive liver markers kept improving on pemvidutide through 48 weeks, with nausea more common in the higher-dose arm.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 212
- Published
- 2026
- Journal
- Lancet Gastroenterol Hepatol
What they tested
The team tested whether 48 weeks of weekly pemvidutide improves liver fat, liver inflammation and liver scarring markers in people with MASH (metabolic dysfunction-associated steatohepatitis, a fatty liver disease with inflammation) compared with placebo.
How the study was done
In this randomized, double-blind, placebo-controlled phase 2b trial, 212 people with biopsy-confirmed MASH and stage F2 or F3 fibrosis (liver scarring) were assigned to pemvidutide 1.2 mg, pemvidutide 1.8 mg or placebo (a dummy shot), each given once a week under the skin. Treatment lasted 48 weeks and started at the full dose, and patients were enrolled from 83 hospitals and research clinics across two countries, the USA and Australia.

What they found
At week 48, liver fat fell by 45.2% in the 1.2 mg arm and 54.7% in the 1.8 mg arm, versus 8.2% on placebo. Corrected T1 relaxation time, an imaging measure, dropped by 124.2 ms and 139.5 ms on pemvidutide versus 20.5 ms on placebo, and ALT, a liver enzyme in the blood, fell by 37.8 and 37.4 IU/L versus 10.3 IU/L on placebo. The enhanced liver fibrosis score fell by 0.49 and 0.58 on pemvidutide but rose by 0.16 on placebo. Nausea was the most common side effect, in 22% of the 1.2 mg arm, 41% of the 1.8 mg arm and 17% of the placebo arm, and no severe or serious side effects were judged to be caused by the drug.
What it doesn’t show
No liver biopsies were taken at week 48, so these results rest on non-invasive tests and are secondary endpoints, not the trial's main biopsy-based goals, which were measured at week 24. It was a mid-size phase 2b trial funded by Altimmune.
The paper
Noureddin et al. Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 48-week results from a multicentre, randomised, double-blind, phase 2b study. Lancet Gastroenterol Hepatol. 2026.
The compound
More studies on Pemvidutide
- Pemvidutide: up to 76.4% liver fat reduction at 24 weeks in MASLDRandomized trial · people · 2025
- Pemvidutide: MASH resolved in up to 58% vs 20% on placebo at 24 weeksRandomized trial · people · 2025
- Pemvidutide cut body weight about 25% in mice with NASHAnimal study · mice · 2022
- Every study on Pemvidutide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.